COVID-19 Biorepository

MUSC has established a COVID-19 biorepository that includes samples from patients known to be COVID-19 positive and negative. The samples include DNA/RNA, serum, plasma, PBMCs, nasopharyngeal (NP) swabs used for testing, as well as longitudinal samples from convalescent patients. Because these specimens represent a finite resource, an oversight committee has been formed to review requests to obtain samples.

Currently, the COVID-19 Biorepository contains samples from 235 unique patients. (last updated 8/26/2022)

Application Process

To apply for samples, please complete the initial REDCap below. The following information will be required to complete the process:

  • Names and affiliations of investigators associated with the project
  • PI biosketch
  • Funding source for the project
  • Type of samples requested, amounts and frequency (if applicable)
  • Scientific background and rationale for the project
  • Hypotheses and Specific Aims
  • Experimental design, including sample size calculation
  • Data analysis plan
  • Expected outcomes and impacts

COVID-19 Biorepository Request Application

RFA to Conduct Research

The RFA To Conduct Research With Biospecimens Obtained from Patients with COVID-19 aims to answer important questions concerning the pathogenesis and sequelae of COVID-19.

Review of Applications

Applications will be reviewed in accordance with the following criteria:

(1) Availability of samples requested
(2) Overall scientific merit of the study
(3) Feasibility of the study, including statistical significance
(4) Potential impact on the prevention or treatment of COVID-19
(5) Expertise of the investigative team
(6) Involvement of MUSC investigators

Please note the following:

• Only applications received through the REDCap site can be accepted
• Applications will be reviewed on a rolling basis
• Samples will only be released if the relevant IRB/IBC approvals are in place
• A progress report on the study is expected after 6 months

Please note that there is an administrative charge to obtain samples from the COVID-19 Biorepository. Contact Amy Gandy for more information.

*PBMC cell counts are 1.0 x 107/1mL

Related News

Giving Back to Defeat COVID-19 - November 5, 2020

COVID-19 Biorepository - June 19, 2020

COVID-19 Research - April 23, 2020

COVID-19 Sample Breakdown

780

DNA

2400

PBMCs

5974

Plasma

624

RNA

1037

Saliva

4976

Serum

Contacts

Dr. Patrick Flume

Patrick Flume, MD
843-792-3167
flumepa@musc.edu

Amy Gandy

Amy Gandy
843-792-2595
gandya@musc.edu